Cyclerion Therapeutics (CYCN) Competitors $2.56 -0.09 (-3.21%) Closing price 08/1/2025 03:49 PM EasternExtended Trading$2.64 +0.08 (+3.12%) As of 08/1/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCN vs. XLO, AKTX, MAAQ, SNYR, RANI, DYAI, ESLA, RNTX, PMN, and BDRXShould you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Xilio Therapeutics (XLO), Akari Therapeutics (AKTX), Mana Capital Acquisition (MAAQ), Synergy CHC (SNYR), Rani Therapeutics (RANI), Dyadic International (DYAI), Estrella Immunopharma (ESLA), Rein Therapeutics (RNTX), Promis Neurosciences (PMN), and Biodexa Pharmaceuticals (BDRX). These companies are all part of the "pharmaceutical products" industry. Cyclerion Therapeutics vs. Its Competitors Xilio Therapeutics Akari Therapeutics Mana Capital Acquisition Synergy CHC Rani Therapeutics Dyadic International Estrella Immunopharma Rein Therapeutics Promis Neurosciences Biodexa Pharmaceuticals Xilio Therapeutics (NASDAQ:XLO) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability. Which has preferable valuation and earnings, XLO or CYCN? Cyclerion Therapeutics has lower revenue, but higher earnings than Xilio Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXilio Therapeutics$6.34M5.31-$58.24M-$0.84-0.77Cyclerion Therapeutics$2M4.12-$3.06M-$1.16-2.21 Does the media prefer XLO or CYCN? In the previous week, Xilio Therapeutics had 2 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for Xilio Therapeutics and 0 mentions for Cyclerion Therapeutics. Xilio Therapeutics' average media sentiment score of 0.37 beat Cyclerion Therapeutics' score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Xilio Therapeutics Neutral Cyclerion Therapeutics Neutral Which has more volatility and risk, XLO or CYCN? Xilio Therapeutics has a beta of -0.15, indicating that its share price is 115% less volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Do analysts prefer XLO or CYCN? Xilio Therapeutics currently has a consensus price target of $4.00, indicating a potential upside of 515.38%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Xilio Therapeutics is more favorable than Cyclerion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cyclerion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals hold more shares of XLO or CYCN? 54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 5.2% of Xilio Therapeutics shares are held by company insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is XLO or CYCN more profitable? Cyclerion Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -585.54%. Cyclerion Therapeutics' return on equity of -34.02% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xilio Therapeutics-585.54% -262.69% -64.01% Cyclerion Therapeutics N/A -34.02%-30.68% SummaryXilio Therapeutics beats Cyclerion Therapeutics on 9 of the 16 factors compared between the two stocks. Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCN vs. The Competition Export to ExcelMetricCyclerion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.51M$2.99B$5.49B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-2.2117.7428.8623.83Price / Sales4.12178.75371.4866.02Price / CashN/A41.9535.4557.96Price / Book0.788.508.275.54Net Income-$3.06M-$55.06M$3.25B$259.28M7 Day Performance-10.31%-3.99%-3.73%-4.68%1 Month Performance-22.27%9.58%4.29%4.36%1 Year Performance-33.72%6.70%25.87%17.89% Cyclerion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCNCyclerion TherapeuticsN/A$2.57-3.2%N/A-26.5%$8.51M$2M-2.2130Positive NewsUpcoming EarningsXLOXilio Therapeutics3.2315 of 5 stars$0.68-2.1%$4.00+486.5%-31.6%$36.08M$6.34M-0.8170News CoverageAKTXAkari Therapeutics2.6884 of 5 stars$1.14+1.3%$5.00+340.5%-73.1%$36.04MN/A0.009High Trading VolumeMAAQMana Capital AcquisitionN/A$4.39-4.2%N/A+875.0%$35.65MN/A0.001Gap DownSNYRSynergy CHC3.875 of 5 stars$3.72-1.8%$10.00+168.8%+3,260.0%$34.85M$34.83M0.0040Trending NewsRANIRani Therapeutics1.9036 of 5 stars$0.55+3.6%$7.33+1,231.2%-80.6%$33.63M$1.03M-0.56110Negative NewsUpcoming EarningsShort Interest ↑DYAIDyadic International2.0793 of 5 stars$1.11+0.9%$6.00+440.5%-25.6%$33.10M$3.49M-5.557News CoveragePositive NewsGap UpESLAEstrella Immunopharma2.9551 of 5 stars$0.92+1.1%$16.00+1,639.1%-51.2%$32.91MN/A-3.54N/ARNTXRein TherapeuticsN/A$1.41-3.4%N/AN/A$32.34MN/A-0.499Positive NewsPMNPromis Neurosciences2.288 of 5 stars$0.90-8.8%$4.33+381.4%-46.8%$32.25MN/A-18.005Upcoming EarningsShort Interest ↑Gap DownBDRXBiodexa Pharmaceuticals0.1034 of 5 stars$0.88flatN/AN/A$32.16MN/A0.0020News CoverageAnalyst DowngradeShort Interest ↑Gap Down Related Companies and Tools Related Companies XLO Competitors AKTX Competitors MAAQ Competitors SNYR Competitors RANI Competitors DYAI Competitors ESLA Competitors RNTX Competitors PMN Competitors BDRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
